iib/iiia

GPRP acetate (Pefabloc FG) is fibrinogen-related peptides, which inhibit the interaction of fibrinogen with the platelet membrane glycoprotein IIbIIIa complex (GPIIbIIIa).

Roxifiban acetate(DMP 754 acetate) is a potent GP IIb / IIIa antagonist that exhibits antiplatelet aggregation activity via immune mediation and can be used in the study of human thrombocytopenia.

Lefradafiban(BIBU-104) is an oral platelet glycoprotein IIb/IIIa receptor antagonist for the study of angina pectoris and acute coronary syndromes.

Gantofiban is a glycoprotein IIb/IIIa (GP IIb/IIIa) antagonist used in the treatment of cardiovascular disease and may be used to study thrombosis.

Elarofiban(RWJ-53308) is a novel and orally active GPIIb/IIIa antagonist.

Elarofiban TFA (RWJ-53308 TFA) is a novel and orally active and selective GPIIb/IIIa antagonist for the study of cardiovascular disease.

Orbofiban TFA is an orally active GPIIb/IIIa platelet receptor antagonist with inhibitory effects on platelet aggregation for the study of unstable coronary syndromes.

Tirofiban(MK383) hydrochloride monohydrate is a non-peptide glycoprotein IIb/IIIa antagonist.

MNS is a tyrosine kinases inhibitor, inhibits Syk, Src, p97 with IC50 of 2.5 μM, 29.3 μM and 1.7 μM, respectively.

Fradafiban binds to the human platelet GP IIb/IIIa complex with a Kd value of 148 nM. Fradafiban is a non-polypeptide platelet glycoprotein IIb/IIIa antagonist.

SR121566A is a novel non-peptide antagonist of Glycoprotein IIb/IIIa (GP IIb-IIIa).

Abciximab (C7E3) is a mouse/human chimeric monoclonal antibody that is a potent glycoprotein IIb/IIIa inhibitor. Abciximab has anti-platelet aggregation and leukocyte adhesion, acting by binding to glycoproteins IIb/IIIa, vitronectin and Mac-1 receptors.

Tirofiban (L700462) (MK-383) is a selective palate GPIIb/IIIa antagonist which inhibits platelet aggregation with IC50 of 9 nM.

Orbofiban, an orally administered antagonist of the platelet GPIIb/IIIa receptor, effectively inhibits platelet aggregation.

Roxifiban, a prodrug of XV459, is an antiplatelet agent with high affinity and specificity for platelet glycoprotein IIb/IIIa complex(GPIIb/IIIa) receptors.

Euchrestaflavanone A is a useful organic compound for research related to life sciences and the catalog number is T124187.

Tirofiban HCl is an antagonist of platelet glycoprotein-IIb/IIIa receptor.

ZD 2486 is a glycoprotein IIb/IIIa (GP IIb/IIIa) antagonist. It inhibits platelet aggregation by blocking the binding of fibrinogen to the GP IIb/IIIa receptors on platelets. ZD 2486 is applicable in research concerning diseases linked to undesirable platelet aggregation, such as acute coronary syndromes, unstable angina, acute myocardial infarction, and complications from cardiovascular interventions.

UR-12947 is a glycoprotein (GP) IIb-IIIa antagonist that effectively inhibits platelet aggregation in human platelet-rich plasma, with an IC50 value of 3.5 nM. It is utilized for the study of arterial thrombotic diseases.

GR 144053 trihydrochloride is a potent and selective GPIIb/IIIa receptor antagonist (IC50 = 20 nM). It inhibits fibrinogen-mediated platelet aggregation, used for thrombosis and antiplatelet drug discovery research.

DMP 728 is an antagonist of Glycoprotein IIb-IIIa.

MK 0852 is the platelet GP IIb/IIIa cyclic heptapeptide antagonist.

SK&F 107260 is an RGD-containing peptide. It is a potent GP IIb/IIIa antagonist and a vitronectin antagonist.

Lamifiban is a nonpeptide glycoprotein IIb/IIIa antagonist. It prevents platelet loss during experimental cardiopulmonary bypass.